Clinical Trials Logo

Unresectable Malignant Neoplasm clinical trials

View clinical trials related to Unresectable Malignant Neoplasm.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04870879 Recruiting - Clinical trials for Colorectal Adenocarcinoma

Colorectal Metastasis and Liver Transplantation With Organs From Deceased Donors

MELODIC
Start date: October 1, 2020
Phase: N/A
Study type: Interventional

MELODIC trial is an prospective, multicenter, non-randomized, open-label, parallel trial, aimed at assessing the efficacy (in terms of overall survival: OS) of liver transplantation (LT) in unresecable CRC liver-only metastases, compared with a matched cohort of patients bearing the same tumor characteristics, and treated with chemotherapy. Synthesis of Inclusion parameters: "10;10;10;100"

NCT ID: NCT04278287 Recruiting - Esophageal Cancer Clinical Trials

Chemoradiotherapy in Unresectable Esophageal Cancer

Start date: October 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II clinical study is designed to evaluate the 1 year local tumor control rate of chemoradiotherapy using albumin-bound paclitaxel and cisplatin in unresectable esophageal squamous cell carcinomas based on Nutritional Risk Screening NRS2002.

NCT ID: NCT04207918 Recruiting - Esophageal Cancer Clinical Trials

A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer

Start date: November 14, 2019
Phase: Phase 2
Study type: Interventional

This phase II clinical study is designed to evaluate the 1 year local tumor control rates after the targeted therapy of intensity-modulated radiation therapy synchronized chemotherapy with nimotuzumab combined with S-1 in local advanced esophageal squamous cell carcinomas based on Nutritional Risk Screening NRS2002.

NCT ID: NCT03777813 Recruiting - Esophagus Cancer Clinical Trials

Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer

ARION
Start date: December 5, 2018
Phase: Phase 2
Study type: Interventional

This study aims to assess the efficacy of durvalumab in combination with radiochemotherapy (FOLFOX and IMRT) and then as maintenance therapy for treating patients with localised unresectable oesophageal cancer. This is a randomized, French national, multicentre, comparative phase II trial